Atossa Therapeutics, Inc.

NasdaqCM:ATOS Stock Report

Market Cap: US$104.4m

Atossa Therapeutics Management

Management criteria checks 3/4

Atossa Therapeutics' CEO is Steve Quay, appointed in Apr 2009, has a tenure of 15.83 years. total yearly compensation is $2.36M, comprised of 30% salary and 70% bonuses, including company stock and options. directly owns 0.002% of the company’s shares, worth $2.20K. The average tenure of the management team and the board of directors is 2.3 years and 13 years respectively.

Key information

Steve Quay

Chief executive officer

US$2.4m

Total compensation

CEO salary percentage30.0%
CEO tenure15.8yrs
CEO ownership0.002%
Management average tenure2.3yrs
Board average tenure13yrs

Recent management updates

Recent updates

We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth

Nov 12
We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth

Atossa Therapeutics: Important News, But The Company Still Has A Long Way To Go

Nov 08

We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth

Jul 01
We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth

Atossa Therapeutics (NASDAQ:ATOS) Is In A Good Position To Deliver On Growth Plans

Mar 07
Atossa Therapeutics (NASDAQ:ATOS) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

Nov 08
We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

Companies Like Atossa Therapeutics (NASDAQ:ATOS) Are In A Position To Invest In Growth

Apr 26
Companies Like Atossa Therapeutics (NASDAQ:ATOS) Are In A Position To Invest In Growth

We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

Jan 09
We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

Atossa Therapeutics: Still Gets An 'Incomplete' Rating

Oct 11

We're Hopeful That Atossa Therapeutics (NASDAQ:ATOS) Will Use Its Cash Wisely

Sep 25
We're Hopeful That Atossa Therapeutics (NASDAQ:ATOS) Will Use Its Cash Wisely

Atossa Therapeutics GAAP EPS of -$0.05

Aug 08

Companies Like Atossa Therapeutics (NASDAQ:ATOS) Are In A Position To Invest In Growth

May 12
Companies Like Atossa Therapeutics (NASDAQ:ATOS) Are In A Position To Invest In Growth

A First Assessment On Atossa Therapeutics

Dec 10

We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

Dec 02
We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

Atossa Therapeutics: Diversification Into COVID Makes Sense In A Variants World

Sep 22

Atossa Therapeutics (NASDAQ:ATOS) Is In A Strong Position To Grow Its Business

Jul 17
Atossa Therapeutics (NASDAQ:ATOS) Is In A Strong Position To Grow Its Business

Atossa Therapeutics: Hope Springs Eternal

Jun 30

Atossa Therapeutics to be included in the Russell 2000, 3000 indexes

Jun 16

Atossa reaches a two-year high ahead of data readout for breast cancer therapy

Jun 07

Atossa Therapeutics (NASDAQ:ATOS) Is In A Good Position To Deliver On Growth Plans

Apr 02
Atossa Therapeutics (NASDAQ:ATOS) Is In A Good Position To Deliver On Growth Plans

Atossa updates on single-patient study for Endoxifen

Feb 04

Atossa halts Endoxifen breast cancer study after positive data

Feb 02

Atossa Therapeutics prices ~$25M direct offering, stock -23% PM

Jan 06

Atossa Therapeutics prices $14M registered direct offering

Dec 17

CEO Compensation Analysis

How has Steve Quay's remuneration changed compared to Atossa Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$27m

Jun 30 2024n/an/a

-US$26m

Mar 31 2024n/an/a

-US$30m

Dec 31 2023US$2mUS$706k

-US$30m

Sep 30 2023n/an/a

-US$30m

Jun 30 2023n/an/a

-US$32m

Mar 31 2023n/an/a

-US$28m

Dec 31 2022US$3mUS$706k

-US$27m

Sep 30 2022n/an/a

-US$24m

Jun 30 2022n/an/a

-US$21m

Mar 31 2022n/an/a

-US$22m

Dec 31 2021US$6mUS$659k

-US$21m

Sep 30 2021n/an/a

-US$28m

Jun 30 2021n/an/a

-US$26m

Mar 31 2021n/an/a

-US$23m

Dec 31 2020US$3mUS$601k

-US$22m

Sep 30 2020n/an/a

-US$13m

Jun 30 2020n/an/a

-US$13m

Mar 31 2020n/an/a

-US$16m

Dec 31 2019US$6mUS$601k

-US$17m

Sep 30 2019n/an/a

-US$17m

Jun 30 2019n/an/a

-US$17m

Mar 31 2019n/an/a

-US$25m

Dec 31 2018US$2mUS$582k

-US$23m

Compensation vs Market: Steve's total compensation ($USD2.36M) is above average for companies of similar size in the US market ($USD638.32K).

Compensation vs Earnings: Steve's compensation has been consistent with company performance over the past year.

CEO

Steve Quay (73 yo)

15.8yrs

Tenure

US$2,356,220

Compensation

Dr. Steven C. Quay, also known as Steve, M.D., Ph D., FCAP, has been the Chief Executive Officer and President of Atossa Therapeutics, Inc. (formerly known as Atossa Genetics Inc.) since April 30, 2009 and...

Leadership Team

NamePositionTenureCompensationOwnership
Steven Quay
Chairman15.8yrsUS$2.36m0.0021%
$ 2.2k
Heather Rees
Chief Financial Officer1.3yrsUS$687.46k0%
$ 0
Delly Behen
Senior Vice President of Administration & HR10.6yrsno datano data
Michael Parks
Vice President of Investor & Public Relations1.1yrsno datano data
Richard Graydon
Interim Chief Medical Officer2.3yrsno datano data

2.3yrs

Average Tenure

Experienced Management: ATOS's management team is considered experienced (2.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Steven Quay
Chairman15.8yrsUS$2.36m0.0021%
$ 2.2k
Richard Steinhart
Independent Director10.9yrsUS$146.17k0%
$ 0
H. Remmel
Independent Director13yrsUS$144.92k0.00020%
$ 208.9
Shu-Chih Chen
Director15.8yrsUS$116.17k0.018%
$ 18.5k
Stephen Galli
Independent Director13.6yrsUS$144.92k0.000080%
$ 83.6
Jonathan Finn
Independent Director1.3yrsUS$93.98k0.020%
$ 20.8k
Tessa Cigler
Independent Directorless than a yearno datano data

13.0yrs

Average Tenure

67yo

Average Age

Experienced Board: ATOS's board of directors are seasoned and experienced ( 13 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/16 10:21
End of Day Share Price 2025/02/14 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Atossa Therapeutics, Inc. is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Edward WooAscendiant Capital Markets LLC
Pooya HemamiEdison Investment Research
Emily BodnarH.C. Wainwright & Co.